RPG Life Sciences Reports Q2 Profit Decline Amid Revenue and EBITDA Growth
RPG Life Sciences reported a net profit of Rs 28.22 crore for Q2 FY27, down from Rs 36.85 crore the previous year, while revenue rose 16.5% to Rs 211.6 crore. Adjusted EBITDA increased 15% to Rs 50.1 crore, with a 23.7% margin. The domestic formulations segment showed strong volume growth, ranking among the top in the Indian market. The company expanded its API business by creating RPG Active Pharma and acquiring Actis Generics and Raghava Lifesciences, focusing on integration and international growth.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (64/100). Lens Score 39/100.
Outlets measured: news18, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–74/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
freepressjournal broke this story on 30 Oct, 04:49 am. Other outlets followed.
- 1